KPV FDA Status in 2026: Withdrawal, the PCAC Vote, and What Comes Next

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), a fragment studied mostly in cell culture and animal models for anti-inflammatory and antimicrobial activity (Journal of Leukocyte Biology, 2000; Endocrine Reviews, 2008). It is not a brand-name drug, and it should not be confused with full-length alpha-MSH analogs like afamelanotide. This page covers only KPV's regulatory status. For the biology and evidence base, see the KPV pillar page.

Is KPV FDA-approved?

No. KPV has no FDA-approved indication, dose, or formulation. Nothing in this page's regulatory sources changes that. Any compounded KPV product is being sold outside an approved drug pathway, and claims that it is "cleared" or "legal" for compounding are not accurate as of September 2026.

What did the Category 2 withdrawal actually mean?

FDA's bulk drug substance nomination process sorts candidate compounding ingredients into categories, and Category 2 is reserved for substances with identified safety risks significant enough that FDA has said they should not be compounded absent further review. KPV was nominated into consideration under this framework, but the nomination was withdrawn by the nominators themselves. The withdrawal means KPV is no longer sitting in that specific safety-flagged category, per FDA's current Category 2 list page (content current as of April 22, 2026): https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

That is the entire fact. Withdrawal from Category 2 is not a safety clearance, not an approval, and not a statement that KPV lacks risk. It simply means the specific nomination that would have formally flagged it was pulled before FDA acted on it. Readers should not extend this into "FDA reviewed KPV and found it safe."

Does the PCAC vote mean KPV can now be compounded?

Not yet. On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, 1 abstain to recommend that KPV be added to the 503A bulks list, the list of substances pharmacies may legally use for compounding under section 503A of the FDC Act. The meeting record is here: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

Two things matter about that vote. First, the margin was narrow, 8 to 6 with one abstention, which signals real disagreement among committee members rather than a clear consensus. Second, and more important operationally: PCAC recommendations are advisory. The committee cannot add anything to the 503A list itself. That authority rests with HHS and FDA, and as of September 2026 no such final action has been taken. KPV remains off the 503A bulks list, and FDA's own 503A bulk drug substance framework page confirms that no interim enforcement discretion currently covers compounding it: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

So what is KPV's actual status right now?

Three facts, stacked in order of authority:

1. FDA-approved status: None. KPV is not an approved drug under any name.
2. 503A bulks list status: Not listed. Compounding it does not currently have the clear legal footing that 503A listing would provide.
3. Category 2 status: Withdrawn nomination, meaning it is not currently flagged in that specific safety category, but this is a procedural fact, not a safety endorsement.

A recommendation vote from an advisory committee sits outside this hierarchy entirely. It is a signal of where the committee leans, not a regulatory action.

Why does a withdrawn nomination not mean "safe to use"?

Because nomination withdrawal and safety review are two different processes. FDA's Category 2 list exists to flag substances where existing information suggests significant safety risk in compounded use. A withdrawal by the nominator removes that specific listing action, but it does not represent FDA independently evaluating KPV's safety and clearing it. The underlying evidence gap that would have prompted safety scrutiny in the first place, namely that most KPV data comes from cell-culture and animal-model studies rather than controlled human trials (Gastroenterology, 2008; Inflammatory Bowel Diseases, 2008), has not been closed by this procedural step.

Timeline: how this unfolded

A decision rule for reading any KPV regulatory claim

Because this space moves in small procedural steps that get overstated in marketing copy, use this filter before trusting a claim about KPV's legal status:

• If the claim says "FDA approved KPV": false. No approval exists. Reject the claim outright.
• If the claim says "KPV is on the 503A list" or "cleared for compounding": false as of September 2026. Ask for a dated FDA source; if none is given, treat the claim as marketing.
• If the claim says "Category 2 nomination withdrawn": true, but ask what that means. It is a procedural exit, not a safety finding. Do not let it imply FDA reviewed and approved KPV.
• If the claim says "an FDA committee recommended KPV for compounding": true regarding the July 2026 PCAC vote, but a recommendation is not a rule. Ask whether HHS/FDA has taken final action; as of this writing, it has not.
• If a compounding pharmacy states any of the above without a linked, dated FDA source: that is a signal to ask more questions before purchasing, not a green light.

This rule does not tell you whether KPV is effective or safe for a given use. It only tells you whether a regulatory claim about KPV is currently defensible.

What this means if you are considering compounded KPV

The regulatory ambiguity described above sits alongside a separate, equally important question: what human evidence exists for whatever condition KPV is being offered for. Most of the published work is preclinical, covering models of colitis (Inflammatory Bowel Diseases, 2008; Molecular Therapy, 2017), skin inflammation (Journal of Immunology, 2010), and endotoxin response (Journal of Surgical Research, 2006), not confirmed human clinical trials. If you are weighing compounded KPV for a specific condition, that evidence gap matters as much as the regulatory gap. See the KPV dosing considerations page and the KPV evidence for IBD and ulcerative colitis for condition-specific detail, and talk to a prescriber who can explain what compounded, non-approved status means for quality control and liability in your case.

What is established, what is plausible, and what is not established

Established: KPV has no FDA approval. It is not currently on the 503A bulks list. Its Category 2 nomination was withdrawn by the nominators. PCAC voted 8-6-1 in July 2026 to recommend 503A listing, and that vote has not yet resulted in final agency action as of September 2026.

Plausible but unproven: That HHS/FDA will act on the PCAC recommendation in either direction within any particular timeframe. Advisory committee votes sometimes lead to listing, sometimes do not, and timing is not predictable from the vote alone.

Not established: That KPV is safe or effective for any human condition at any specific dose. That withdrawal from Category 2 reflects an FDA safety determination. That the PCAC vote makes compounding KPV legally equivalent to compounding a listed 503A substance.

Anyone encountering urgent adverse effects from a compounded peptide product, including unexpected injection site reactions, systemic symptoms, or signs of infection, should seek medical care rather than trying to self-diagnose the cause.